Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Vimpat
Generic Name: Lacosamide
Lacosamide is an anticonvulsant agent used for adjunctive therapy in the treatment of partial-onset seizures. Lacosamide was previously known as harkoseride and then SPM 927.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Epilepsy | 218 | 65 |
|
|
|
|
|
| Seizures (complex partial) | 38 | 14 |
|
|
|
|
|
| Seizures | 4 | 1 |
|
||||
| Muscle tightness with stiffness | 4 | 1 |
|
||||
| Nerve pain (neuralgia) | 2 | 0 | |||||
| atonic seizures | 1 | 0 |
See all 246 patients currently taking Lacosamide
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Lacosamide
| Dizziness | 9 | |
|---|---|---|
| Double vision (diplopia) | 8 | |
| Nausea | 6 | |
| Excessive daytime sleepiness (somnolence) | 5 | |
| Tiredness | 4 | |
| Stomach upset | 3 | |
| See all 94 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Lacosamide. See all 28 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Side effects too severe | 23 | ||
| Did not seem to work | 19 | ||
| Doctor's advice | 11 | ||
| Other | 8 | ||
| Expense | 6 | ||
| Personal research | 1 | ||
| Course of treatment ended | 1 | ||
| Change in health plan coverage | 1 |
Adherence
Taking treatment as prescribed
Adherence of Lacosamide
Always |
75 | 94% |
|
|---|---|---|---|
Usually |
3 | 4% |
|
Sometimes |
1 | 1% |
|
Never |
1 | 1% |
|
Burden
Difficulty being on treatment
Burden of Lacosamide
Very |
5 | 6% |
|
|---|---|---|---|
Somewhat |
6 | 8% |
|
A little |
14 | 18% |
|
Not at all |
55 | 69% |
|
Cost
Paid out of pocket
Cost of Lacosamide
$200+ |
5 | 9% |
|
|---|---|---|---|
$100-199 |
5 | 9% |
|
$50-99 |
3 | 6% |
|
$25-49 |
8 | 15% |
|
< $25 |
32 | 59% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 23, 2012.